Document:

exv4w3

 

Exhibit 4.3

 

 

QUATRX PHARMACEUTICALS COMPANY

     The following abbreviations, when used in the inscription on the face of this certificate,
shall be construed as though they were written out in full according to applicable laws or
regulations:

	 	 	 
	TEN COM

	 	– as tenants in common
	TEN ENT

	 	– as tenants by the entireties
	JT TEN

	 	– as joint tenants with right of survivorship and not as tenants in common

	 	 	 	 	 	 	 	 	 	 	 
	UNIF GIFT MIN ACT–

	 	 	 	 	 	 	 Custodian 
	 	 	 
	 	 	 	 	 	 	 
	 	 	(Cust)	 	 	 	(Minor)
	 	 	under Uniform Gifts to Minors
	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	Act
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	(State)
	 
	 	 	 	 	 	 	 	 	 	 
	UNIF TRF MIN ACT–

	 	 	 	 	 	 Custodian (until age 	 	)
	 

	 	(Cust)	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 	 under Uniform Transfers
	 

	 	 	 	(Minor)	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	to Minors Act
	 	 	 	 	 	 	 
	 

	 	 	 	(State)	 	 	 	 	 	 

Additional abbreviations may also be used though not in the above list.

For Value received,                                                                                                      hereby sell, assign and transfer unto

	 	 	 
	PLEASE INSERT SOCIAL SECURITY OR OTHER

	 	 
	IDENTIFYING NUMBER OF ASSIGNEE
	 	 
	 

	 	 

      

(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE OF ASSlGNEE)

 

 

                                                                                                                                                                                    
              Shares

of the Capital Stock represented by the within Certificate, and do(es) hereby irrevocably
constitute and appoint

                                                                                                                                                                                    
            Attorney

to transfer the common Stock on the books of the within named Corporation with full power of
substitution in the premises.

	 	 	 	 	 
	Dated 
	 	 	X 	 
	 
	 

	 	 	X 	 
	 

	 	 	NOTICE: 
	THE SIGNATURE(S) TO THIS ASSIGNMENT
MUST CORRESPOND WITH THE NAME(S) AS
WRITTEN UPON THE FACE OF THE
CERTIFICATE IN EVERY PARTICULAR WITHOUT
ALTERATION OR ENLARGEMENT OR ANY CHANGE
WHATEVER.

SIGNATURES GUARANTEED:

	 	 	 
	By
	 	 
	 

	 	THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION
(BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH
MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM). PURSUANT
TO S.E.C. RULE 17Ad-l5.<PAGE>

                                                                    Exhibit 10.9

                                                               Agreement 02-0207

                                   AGREEMENT
                                   ---------

     This Agreement ("Agreement") is made effective the 9th day of November,
2001, by and between Wisconsin Alumni Research Foundation (hereinafter called
"WARF"), a non-stock, nonprofit Wisconsin corporation, and Quatrx
Pharmaceuticals Company, (hereinafter called "Quatrx"), a corporation organized
and existing under the laws of the State of Delaware;

     WHEREAS, WARF has entered into that certain Deltanoid License Agreement
dated April 7, 2000 by and between WARF and Deltanoid Pharmaceuticals, Inc.
("Deltanoid"), a copy of which is attached hereto as Exhibit A (the "Deltanoid
Agreement");

     WHEREAS, under the terms of the Deltanoid Agreement, WARF licensed to
Deltanoid rights in certain compounds and inventions described in the Deltanoid
Agreement (the "Deltanoid Rights");

     WHEREAS, contemporaneous with the execution of this Agreement, Quatrx will
enter into an agreement with Deltanoid (a copy of which is attached hereto as
Exhibit B) pursuant to which Deltanoid shall sublicense to Quatrx certain
Deltanoid Rights (the "Deltanoid-Quatrx Agreement").

     WHEREAS, WARF and Quatrx desire to provide for the continued ability of
Quatrx to research, develop and commercialize product based on the Deltanoid
Rights even in the event that the Deltanoid Agreement is terminated.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set
forth below, the parties covenant and agree as follows:

Section 1. Consequence of Termination of Deltanoid Agreement.
           -------------------------------------------------

          In the event that (a) the Deltanoid Agreement is terminated for any
reason and (b) Quatrx has not breached the Deltanoid-Quatrx Agreement, then WARF
and Quatrx shall be deemed to have entered into an agreement identical to the
Deltanoid-Quatrx Agreement except that WARF shall be substituted for Deltanoid
in that agreement (such new agreement is hereinafter referred to as the "New
WARF-Quatrx Agreement"). In the event that WARF is prohibited by any applicable
law, rule or regulation from entering into the New WARF-Quatrx Agreement, or
WARF'S entering into such New WARF-Quatrx Agreement would adversely affect its
non-profit status, then the parties agree to enter into an agreement (the
"Modified New WARF-Quatrx Agreement") whereby (w) WARF shall license to Quatrx
the Deltanoid Rights licensed to Quatrx in the Deltanoid-Quatrx Agreement, (x)
such new agreement shall require payment to WARF of a royalty on net sales of
products based on the Deltanoid Rights which royalty is no higher than that set
forth in the Deltanoid-Quatrx Agreement, (y) such new agreement shall require
the payment to WARF of other fees and milestones no different than those set
forth in the Deltanoid-Quatrx Agreement (less the amount of any such fees
already paid by Quatrx to Deltanoid) and (z) all other economic terms of such
agreement shall be the same as set forth in the Deltanoid-Quatrx Agreement.

Section 2. Cooperation.
           -----------

     In the event that a New WARF-Quatrx Agreement or a Modified New WARF-Quatrx
Agreement is entered into by the parties, WARF and Quatrx hereby agree to
cooperate in the exchange of such information, including, without limitation,
pre-clinical and clinical research reports, patent applications and related
prosecution histories, and other documentation as shall be necessary to permit
the continued and uninterrupted research, development and commercialization of
products based on the Deltanoid Rights to the extent such information is in the
possession of WARF and Quatrx respectively.

<PAGE>

Section 3.     Miscellaneous.

          This Agreement shall be governed by and construed in all respects in
accordance with the laws of the State of Wisconsin. If any provisions of this
Agreement are or shall come into conflict with the laws or regulations of any
jurisdiction or any governmental entity having jurisdiction over the parties
or this Agreement, those provisions shall be deemed automatically deleted, if
such deletion is allowed by relevant law, and the remaining terms and
conditions of this Agreement shall remain in full force and effect. If such a
deletion is not so allowed or if such a deletion leaves terms thereby made
clearly illogical or inappropriate in effect, the parties agree to substitute
new terms as similar in effect to the present terms of this Agreement as may be
allowed under the applicable laws and regulations. The parties hereto are
independent contractors and not joint venturers or partners.

Section 4.     Notices.

          Any notice required to be given pursuant to the provisions of this
Agreement shall be in writing and shall be deemed to have been given at the
earlier of the time when actually received as a consequence of any effective
method of delivery, including but not limited to hand delivery, transmission by
telecopier, or delivery by a professional courier service or the time when sent
by certified or registered mail or a nationally recognized overnight delivery
service addressed to the party for whom intended at the address below or at such
changed address as the party shall have specified by written notice, provided
that any notice of change of address shall be effective only upon actual
receipt.

          (a)  Wisconsin Alumni Research Foundation
               Attn: Managing Director
               614 Walnut Street
               Madison, Wisconsin 53705

          (b)  Quatrx Pharmaceuticals, Inc.
               5430 Data Court, Suite 300
               Ann Arbor, MI 48108
               Attention: CEO
               Telephone: 734-913-0743
               Telecopy:  734-913-9900

Section 5.     Integration.

          This Agreement constitutes the full understanding between the parties
with reference to the subject matter hereof, and no statements or agreements by
or between the parties, whether orally or in writing, except as provided for
elsewhere in this Section 5, made prior to or at the signing hereof, shall vary
or modify the written terms of this Agreement. Neither party shall claim any
amendment, modification, or release from any provisions of this Agreement by
mutual agreement, acknowledgment, or otherwise, unless such mutual agreement is
in writing, signed by the other party, and specifically states that it is an
amendment to this Agreement.

Section 6.     Authority.

          The persons signing on behalf of WARF and Quatrx hereby warrant and
represent that they have authority to execute this Agreement on behalf of the
party for whom they have signed and that each such contracting party is
authorized to enter into this Agreement. The execution, delivery and
performance of this Agreement by such Party does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a Party
or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.

<PAGE>
Section 7.  Counterparts.

     This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original and all of which together shall constitute
one and the same instrument.

     IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement
on the dates indicated below.

 WISCONSIN ALUMNI RESEARCH FOUNDATION

By: /s/ Carl E. Gulbrandsen                  Date: 11/14, 2001
   --------------------------------------          --------------------
   Carl E. Gulbrandsen, Managing Director

 QUATRX PHARMACEUTICALS COMPANY

By: /s/ ROBERT L. ZERBE                      Date: 11/9, 2001
   --------------------------------------          --------------------
Name and Office: ROBERT L. ZERBE
                -------------------------------------------------------
  CHIEF EXECUTIVE OFFICER
--------------------------------------
Reviewed by WARF's Attorney:

/s/ Elizabeth L.R. Donley                          11/14, 2001
-----------------------------------------          --------------------
Elizabeth L.R. Donley, Esq.

(WARF's attorney shall not be deemed a signatory to this Agreement.)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]